Complete DiGeorge Syndrome: Clinical Trials

6 trials for Complete DiGeorge Syndrome, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

5 completed, 1 recruiting. 3 Phase 1, 2 Phase 2, 1 Not applicable.

By phase and status

PhaseTrialsStatus
Phase 13Completed 3
Phase 22Completed 2
Not applicable1Completed 1

Follow Complete DiGeorge Syndrome: new trials by email Literature Review of Complete DiGeorge Syndrome trials Research Report on Complete DiGeorge Syndrome

Trials newest first · largest first

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Congenital Athymia Patient Registry
Cultured Thymus Tissue - Complete DiGeorge Anomaly, Complete DiGeorge Syndrome
RecruitingSumitomo Pharma Switzerland GmbH752022-05-252025-08-19
Thymus Transplantation Safety-Efficacy
Cultured Thymus Tissue - Complete DiGeorge Anomaly, DiGeorge Syndrome
Not applicableCompletedSumitomo Pharma Switzerland GmbH292010-12-012025-01-16
Phase I/II Thymus Transplantation With Immunosuppression #950
Cultured Thymus Tissue for Implantation (CTTI), Cultured Thymus Tissue Implantation and Parental Parathyroid Transplantation, Blood Draw - DiGeorge Anomaly, Complete DiGeorge Anomaly
Phase 1 / Phase 2CompletedSumitomo Pharma Switzerland GmbH142005-12-192022-03-25
Parathyroid and Thymus Transplantation in DiGeorge #931
Thymus/Parathyroid Transplantation - DiGeorge Syndrome, Hypoparathyroidism
Phase 1CompletedSumitomo Pharma Switzerland GmbH252005-01-012022-04-04
Thymus Transplantation Dose in DiGeorge #932
Cultured Thymus Tissue Implantation (CTTI), Cultured Thymus Tissue Implantation with Parathyroid Transplantation - DiGeorge Anomaly, DiGeorge Syndrome
Phase 2CompletedSumitomo Pharma Switzerland GmbH72004-09-022022-03-25
Thymus Transplantation With Immunosuppression
Thymus Tissue for Transplantation - DiGeorge Syndrome, DiGeorge Anomaly
Phase 1CompletedSumitomo Pharma Switzerland GmbH152002-07-012022-04-04

Narrower conditions

DiGeorge Syndrome (5)  ·  Thymic aplasia (5)  ·  Immunologic Deficiency Syndromes (4)  ·  Hypoparathyroidism (3)  ·  Hypocalcemia (2)

Broader conditions

22q11 Deletion Syndrome (5)  ·  Abnormalities, Multiple (5)  ·  Cardiovascular Abnormalities (5)  ·  Cardiovascular Diseases (5)  ·  Chromosome Disorders (5)  ·  Congenital Abnormalities (5)  ·  Congenital, Hereditary, and Neonatal Diseases and Abnormalities (5)  ·  Craniofacial Abnormalities (5)  ·  Endocrine System Diseases (5)  ·  Genetic Diseases, Inborn (5)  ·  Heart Defects, Congenital (5)  ·  Heart Diseases (5)  ·  Hemic and Lymphatic Diseases (5)  ·  Lymphatic Abnormalities (5)  ·  Lymphatic Diseases (5)

Interventions

Thymus Extracts (3)  ·  Transplantation (2)  ·  Antilymphocyte Serum (1)  ·  Blood Specimen Collection (1)  ·  Cyclosporine (1)  ·  Cyclosporins (1)  ·  Daclizumab (1)  ·  Drug Implants (1)  ·  Methylprednisolone (1)  ·  Mycophenolic Acid (1)  ·  Phlebotomy (1)  ·  Prednisolone (1)  ·  Steroids (1)  ·  Tacrolimus (1)  ·  thymoglobulin (1)

Sponsors

Sumitomo Pharma Switzerland GmbH (6)

Countries

United States (6)

Top investigators

M. Louise Markert, MD, PhD (4)  ·  John W. Sleasman, M.D. (1)

Results publications

PMID 18035553, PMID 18424759, PMID 18557726, PMID 19066739, PMID 20236866, PMID 17284531, PMID 15100156, PMID 23607606, PMID 15100681, PMID 18155964, PMID 18333898, PMID 20978268, PMID 21565561, PMID 22590644, PMID 23914737

NIH funding

K12HD043494 (5), R01AI047040 (5), R01AI054843 (4), R56AI047040 (3)